The reconsideration follows an Oct. 11 lawsuit that prompted U.S. District Judge Mark Pittman to temporarily halt legal proceedings to give the FDA time to reassess its ruling.
The UK Government has signed a collaboration agreement with Lilly, the pharmaceutical giant behind weight loss medication ...
Hims & Hers Health (HIMS) is enjoying a morning surge after the Food and Drug Administration (FDA) dropped fresh news ...
A rapid-fire reversal from the Food and Drug Administration has injected even more uncertainty into what was already a wild ...
In win for compounders, FDA will review its decision to put Eli Lilly's tirzepatide on shortage list
In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities ...
The FDA resolved the shortage of Eli Lilly's tirzepatide, but may revisit allowing compounding pharmacies to make copies, ...
Lilly’s latest investment comes on the heels of three earlier rounds of manufacturing investment at the LEAP Research and ...
Analysts say the number of private prescriptions for fat busting jabs like Ozempic in the UK are predicted to soar to over ...
An online store has jumped on the Ozempic craze by releasing a “sexy” semaglutide injection costume just in time for ...
Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no ...
One of the downsides of treatments such as Ozempic or Mounjaro is that even though patients wind up losing weight, they also tend to shed muscle mass. Losing too much muscle mass can be a health risk ...
A pharmacist warns that off-brand Ozempic, Zepbound, and other weight loss products carry undisclosed risks for consumers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback